Hyderabad, Dec. 29 -- Mumbai-based drug major Lupin on Monday said it has entered into an exclusive licensing, supply and distribution agreement with China-based Gan & Lee Pharmaceuticals to commercialise Bofanglutide, a novel fortnightly GLP-1 receptor agonist, in India.
The agreement strengthens Lupin's diabetes portfolio and marks its entry into the fast-growing obesity treatment segment, the pharma company said in a release.
Bofanglutide, developed by Gan & Lee, is designed for adults with type 2 diabetes and for weight management in overweight and obese patients.
The injectable therapy is administered once every two weeks, compared with the weekly dosing of currently available GLP-1 drugs.
According to the companies, clinical data ...